Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK-

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016

HEIDELBERG, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD ), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced that the Company presented data on its EGFR-targeting TandAb immune cell engagers on Sunday, April 17, in two poster presentation at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans, LA.

A number of EGFR-targeting drugs have been approved to treat solid tumors including tyrosine kinase inhibitors and monoclonal antibodies such as cetuximab. Despite demonstrated clinical efficacy of such anti-EGFR therapeutics, intrinsic or acquired resistance has been observed in a substantial number of patients and, to date, no meaningful immunotherapeutic effect has been shown. Displaying significant advances over IgG-based antibodies in recruiting NK-cells, Affimed's TandAbs bind NK-cells with higher affinity compared to IgGs and they do not bind to neutrophils, thereby avoiding a diluting effect on NK-cell efficacy. Additionally, TandAbs do not compete with the IgGs circulating in the bloodstream, making the TandAbs more effective. Based on these features, NK-cell TandAbs represent potentially effective immunotherapeutics, overcoming the intrinsic deficits of IgG-based antibodies.

Affimed has developed novel tetravalent, bi-specific TandAbs that recognize EGFRvIII, the most prevalent tumor-specific variant of the epidermal growth factor receptor, and TandAbs that target the wild-type EGFR (EGFRwt), which, when constitutively activated through binding by growth factors or mutations, plays an important role in the pathophysiology of numerous solid cancers such as colorectal, lung or head and neck cancer. The data presented at AACR demonstrate that Affimed's EGFR-targeting preclinical candidates AFM21 (EGFRvIII/CD3), AFM22 (EGFRvIII/CD16A) and AFM24 (EGFR/CD16A) are highly specific and potent drug candidates suitable for the treatment of solid tumors with potentially broader and superior therapeutic properties compared to competitors' products.

"Targeting EGFRwt as well as EGFRvIII provides the opportunity to move beyond hematological malignancies and broaden our TandAb approach into treating solid tumors," said Dr. Martin Treder, CSO of Affimed. "Having the unique opportunity to select either NK- or T-cell engagement for the clinical development of EGFRvIII-targeting TandAbs allows for developing the appropriate effector function in each of the selected clinical indications."

Specifically utilizing the cytotoxic potential of NK-cells for the elimination of EGFR-overexpressing cancer cells, Affimed engineered a set of EGFRwt/CD16A TandAbs and selected ideal candidates based on their binding, thermostability and cytotoxic properties. The selected lead candidate, AFM24, was shown to bind to human and cynomolgus EGFRwt and CD16A, respectively, and was highly stable in buffer and serum. In addition, AFM24 demonstrated high affinity binding and specificity to several EGFR-positive cell lines from different tumor types, with no binding observed to target-negative cells. Directly compared to cetuximab, AFM24 showed superior anti-tumor efficacy in vitro .

The AFM21/22 and AFM24 programs further validate the robustness of Affimed's TandAb technology platform, allowing for rapid identification of candidate molecules which are stable, highly expressed, and display significant in vitro and in vivo cytotoxicity to cancer cells.

About Affimed N.V.

Affimed (Nasdaq: AFMD ) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, collaborations, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

IR Contact: Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: or Media Contact: Anca Alexandru, Head of Communications Phone: +49 6221 64793341 E-Mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 141

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 23

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 8

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 149

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 80

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading

Top 5 Most Recently Viewed Articles

Embassy Bancorp, Inc. Reports Strong Financial Growth for Q2

Updated Category News Views 197

Embassy Bancorp, Inc. Financial Results Overview Embassy Bancorp, Inc. (OTCQX: EMYB) has recently released a comprehensive report highlighting its operations and financial achievements for the quarter ended June 30, 2025. The report outlines the ongoing stability and growth of the company, reinforcing its position in the competitive banking landscape. Key Financial...

Continue Reading
Unlocking New Features: Wijmo 2025 v2 by MESCIUS USA, Inc.

Updated Category News Views 200

Wijmo 2025 v2: A Leap Forward in Enterprise Software MESCIUS USA Inc. has officially launched Wijmo 2025 v2, marking the last major release for the year. This version not only promises cutting-edge features but also showcases their commitment to enhancing developer experiences across frameworks. Included in this release is robust support for Angular 20 and Nuxt.js 4,...

Continue Reading
Titan Investors Teams with Corridor for Global Expansion

Updated Category News Views 42

Titan Investors Takes a Bold Leap Forward Alright folks, here's a change in the wind that's got my attention. Titan Investors, a heavyweight in the investment event business, has just locked arms with Corridor Capital. Yeah, we're talking about a private equity firm with a knack for boosting the game of middle-market business services across North America. If you're...

Continue Reading
Examining the Implications of a 'Shadow' Fed Chair Role

Updated Category News Views 166

The Emerging Concept of a ‘Shadow’ Fed Chair There has been growing tension surrounding Chairman Powell, particularly with rising frustration from Donald Trump. Reports indicate that Trump may expedite his decision on Powell's successor, creating anticipation for a so-called 'shadow Fed Chair' who would shape economic opinions until Powell's term concludes in 2026....

Continue Reading
U.S. Postal Service Reports Growth and Financial Improvements

Updated Category News Views 294

U.S. Postal Service Financial Results Overview The U.S. Postal Service has recently shared its financial outcomes for the first quarter of fiscal year 2025, revealing impressive growth metrics that mark a significant turnaround from previous years. Controllable income has doubled to $968 million, a substantial increase from $472 million during the same period last year,...

Continue Reading